Robert L. Martuza
Affiliations: | Massachusetts General Hospital, Boston, MA |
Google:
"Robert Martuza"Mean distance: 18.87 (cluster 17)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Shimizu K, Kahramanian A, Jabbar MADA, et al. (2023) Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies. Cancer Letters. 572: 216363 |
| Jahan N, Ghouse SM, Martuza RL, et al. (2021) In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV. Viruses. 13 |
| Li M, Li G, Kiyokawa J, et al. (2020) Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathologica Communications. 8: 221 |
| Saha D, Rabkin SD, Martuza RL. (2020) Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. Journal For Immunotherapy of Cancer. 8 |
| Ning JF, Stanciu M, Humphrey MR, et al. (2019) Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nature Communications. 10: 2910 |
| Wang L, Ning J, Wakimoto H, et al. (2019) Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. Molecular Therapy Oncolytics. 13: 58-66 |
| Chongsathidkiet P, Jackson C, Koyama S, et al. (2019) Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine |
| Tanaka S, Luk S, Kiyokawa J, et al. (2019) Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Scientific Reports. 9: 139 |
| Chongsathidkiet P, Jackson C, Koyama S, et al. (2018) Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine |
| Saha D, Martuza RL, Rabkin SD. (2018) Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. Immunotherapy. 10: 779-786 |